Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Articles
Articles
Experts Debate the Role of Maintenance Rituximab in Follicular Lymphoma
By
Alice Goodman
NCCN Congress Highlights
October 2014, Vol 5 , No 8
New York, NY—In a debate on the role of rituximab (Rituxan) maintenance therapy in patients with follicular lymphoma at the 2014 National Comprehensive Cancer Network Congress, the protagonist and antagonist were not that far apart.
Read More
Postresection Routine Surveillance with CT Instead of Chest X-Ray Does Not Improve Survival in Early-Stage Lung Cancer
By
Rosemary Frei, MSc
Lung Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
Toronto, Canada—Survival is not improved with routine surveillance using computed tomography (CT) versus chest x-ray in patients who have undergone resection for stage I non–small-cell lung cancer (NSCLC), according to the results of a new analysis presented at the 2014 American Association for Thoracic Surgery meeting.
Read More
Comparing the Safety and Efficacy of Stereotactic Radiotherapy versus Surgery in Lung Cancer
By
Laura Morgan
Lung Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
San Francisco, CA—The use of stereotactic body radiotherapy (SBRT), also called stereotactic radiotherapy or radiosurgery, is an effective option for elderly patients with cancer who are inoperable or who decline surgery, but its safety and efficacy compared with surgery have not been investigated.
Read More
IOM’s Call to Action on End-of-Life Care in the United States
By
Laura Morgan
End-of-Life Care
,
Policies & Guidelines
October 2014, Vol 5 , No 8
The initiative to improve end-of-life care in the United States is taking center stage, and it is about time. The US population is aging, and the number of older Americans with comorbidities is growing.
Read More
In The Literature - October 2014
In the Literature
October 2014, Vol 5 , No 8
Read More
Multigene Test Stratifies Prostate Cancer Aggressiveness
By
Rosemary Frei, MSc
Prostate Cancer
October 2014, Vol 5 , No 8
Chicago, IL—The commercially available cell-cycle progression test known as Prolaris is helpful for stratifying risk for men with clinically localized prostate cancer and can help to modify treatment decisions for men with prostate cancer based on the aggressive nature of their tumor, according to a poster presented at the 2014 College of American Pathologists annual meeting by Michael K. Brawer, MD, Vice President of Medical Affairs, Urology, Myriad Genetic Laboratories, Inc, Salt Lake City, UT, and colleagues.
Read More
New Practice Guideline for Systemic Therapy in Men with Metastatic Prostate Cancer
By
Rosemary Frei, MSc
Prostate Cancer
October 2014, Vol 5 , No 8
Anew guideline for systemic therapy in men with metastatic castration-resistant prostate cancer (mCRPC) is based on a literature review of recent publications and outlines the survival and quality-of-life benefits/toxicity effects of each recommendation (Basch E, et al.
J Clin Oncol
. 2014 Sept 8. Epub ahead of print).
Read More
Logistic Toxicity: Obstacles to the Efficient Delivery of Cancer Care
By
Barry D. Brooks, MD
Value-Based Care
,
VBCC Perspectives
October 2014, Vol 5 , No 8
The Merriam-Webster dictionary defines “logistics” as the things that must be done to plan and organize a complicated activity that involves many people. The modern delivery of cancer care precisely parallels this definition.
Read More
Study Identifies Important Benefits of Cancer Survivorship Programs
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
San Francisco, CA—Patients with breast cancer who attended survivorship clinics demonstrated improved compliance with follow-up visits, increased use of supportive services, and felt their concerns were better addressed, according to the results of a cancer center’s patient survey reported by Leah L. Dietrich, MD, an oncologist at Gundersen Health System, La Crosse, WI, at the 2014 Breast Cancer Symposium.
Read More
Adding Luteinizing Hormone-Releasing Hormone Agonist to Chemotherapy Preserves Fertility in Women with Breast Cancer
By
Wayne Kuznar
Breast Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
San Francisco, CA—A second study adds to the body of evidence that including a luteinizing hormone-releasing hormone (LHRH) agonist with chemotherapy as treatment for breast cancer increases a younger woman’s likelihood of becoming pregnant.
Read More
Page 211 of 329
208
209
210
211
212
213
214
Top Trending Articles
1.
Immunotherapy Helps Navy Veteran Beat Stage 4 Lung Cancer
2.
HOPA Highlights: What's New in 2025?
3.
Peer Navigation Intervention Aims to Boost Childhood Cancer Clinical Trial Participation
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quiz
Press Releases
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma